EUROAPI Launches Med4Cure Project to Boost Pharmaceutical Innovation
EUROAPI has officially announced the launch of its innovation programs under the Med4Cure project, supported by the European Union, to promote pharmaceutical sovereignty.
Significant Funding and National Support
According to the press release, in June 2024, EUROAPI was selected among 13 European companies to receive public funding of up to one billion euros. In France, the government signed a contractual agreement with EUROAPI in July 2025, providing financial support up to 140 million euros as part of the France 2030 plan, to support the company's innovation initiatives.
Collaborative Efforts with Specialized Partners
The Med4Cure project, officially launched at the Vertolaye site, involves a wide range of partners, including specialized startups and academic institutions. EUROAPI plans to collaborate with companies such as Abolis, Alysophil, and Crysttal, as well as renowned academic establishments, to enhance the sustainable production of active pharmaceutical ingredients in Europe.
Strategic Focus Areas of the Med4Cure Project
The Med4Cure project focuses on three strategic areas: the development of corticosteroids at the Vertolaye site, improving the bioavailability of nanocrystals, and relocating the production of macrolide antibiotics to Saint-Aubin-lès-Elbeuf. According to the company, these initiatives aim to strengthen competitive and sustainable production of active ingredients to meet European health needs.
